Cytodyn Inc (CYDY)

[bluefish1]

From the link you provided. Maybe go back and re-read it.

Survival benefit: A favorable, statistically significant results (p value 0.0319) reported for the primary endpoint (all-cause mortality at Day 28) in participants receiving leronlimab + “commonly used COVID-19 treatments” compared to participants who received “commonly used COVID-19 treatments” alone in the placebo group in the overall mITT population.

Similar statistically significant results (p value 0.0552) reported for the primary endpoint (all-cause mortality at Day 28) among participants who received dexamethasone as the prior or concomitant standard of care treatment for COVID-19, compared to patients who received dexamethasone (without leronlimab) as standard of care therapy in the overall mITT population.